TMEM207 Antibody

Definition and Basic Characteristics

The TMEM207 Antibody is a specialized immunological tool designed to detect the transmembrane protein 207 (TMEM207), a 16.1 kDa membrane protein implicated in cancer progression and hematological disorders. Key features include:

• Target: Human TMEM207 (canonical protein with 146 amino acids), also known as SRSR846 .

• Applications: ELISA, immunohistochemistry (IHC), immunocytochemistry (ICC), and co-immunoprecipitation assays .

• Subcellular Localization: Primarily localized to the cell membrane, with cytoplasmic expression observed in certain cancer cells .

Oral Squamous Cell Carcinoma (OSCC)

• TMEM207 Expression: Detected in 40/90 OSCC samples, absent in non-tumorous epithelial tissues .

• Clinical Correlation:

  • Lymph Node Metastasis: TMEM207-positive OSCC cases showed significantly higher metastasis rates (p < 0.01) .

  • Prognosis: Concomitant expression with Clptm1L correlated with poor survival outcomes .

• Mechanistic Insights:

  • WWOX Interaction: TMEM207 binds WWOX via its PPxY motif, disrupting WWOX-mediated degradation of HIF-1α, promoting aerobic glycolysis .

  • Tumor Growth: Enforced TMEM207 expression in SAS cells increased xenograft tumor size and GLUT-1 expression .

Colorectal Cancer

• Mucinous Phenotype: TMEM207 expression is strongly associated with mucinous carcinomas (18/28 cases) and inversely correlated with lymph node metastasis (p < 0.01) .

• Functional Role:

  • Intelectin-1 Processing: TMEM207 knockdown increases intelectin-1 polyubiquitination, suggesting a role in protein trafficking .

  • WWOX Competition: May inhibit WWOX tumor suppressor activity in colorectal carcinogenesis .

Myeloproliferative Diseases (MPD)

• Mouse Model: Transgenic C57BL/6-Tg (ITF-TMEM207) mice develop myeloproliferative disease-like phenotypes, with TMEM207 detected in megakaryocytes and erythroblasts .

• Human Relevance:

  • CML and MDS: TMEM207 immunoreactivity observed in 3/5 human bone marrow specimens (megakaryocytes in CML, erythroblasts in MDS) .

  • Pathogenic Mechanism: Overexpression may disrupt ATG4B function and WWOX regulation, contributing to hematologic malignancies .

Immunohistochemical Protocols

Validation and Specificity

• Pre-Adsorption Tests: Peptide pre-incubation abolishes immunoreactivity, confirming specificity .

• Cross-Reactivity: No reported cross-reactivity with non-human species unless specified (e.g., mouse monoclonal antibodies) .

Future Directions

• Therapeutic Targeting: TMEM207’s role in WWOX regulation positions it as a potential target for OSCC and colorectal cancer therapies .

• Diagnostic Biomarker: Combined detection of TMEM207 and Clptm1L may improve prognostic accuracy in OSCC .

• Hematological Diseases: Further studies are needed to elucidate TMEM207’s interaction with ATG4B and its role in MPD pathogenesis .

References

1. Biocompare. Anti-TMEM207 Antibody Products. Link

2. Bunai et al. PMC5783854. TMEM207 hinders WWOX in OSCC. Link

3. Maeda et al. Bio. Myeloproliferative mouse model. Link

4. Takeuchi et al. PMC4716854. TMEM207 in colorectal cancer. Link

5. Fisher Scientific. TMEM207 Polyclonal Antibody. Link

6. Frontiers. Clptm1L and TMEM207 in OSCC. Link

7. Wiley. TMEM207 and WWOX in OSCC. Link

8. Biologists. TMEM207 in MPD. Link